Uric acid is the last product of purine metabolism in humans. The formation of uric acid is through the enzyme xanthine oxidase, which oxidizes oxypurines. Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones. As a therapeutic agent, it is known that uric acid is increased in response to oxidative stress, and as such, uric acid acts as an antioxidant. At present (August 2013), there is no approved formulation or indication for uric acid. In one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Regadenoson | Uric acid may decrease effectiveness of Regadenoson as a diagnostic agent. |
| Adalimumab | The serum concentration of Uric acid can be decreased when it is combined with Adalimumab. |
| Adenosine | The therapeutic efficacy of Adenosine can be decreased when used in combination with Uric acid. |
| Allopurinol | The serum concentration of Uric acid can be increased when it is combined with Allopurinol. |
| Carbamazepine | The serum concentration of Uric acid can be decreased when it is combined with Carbamazepine. |
| Cimetidine | The metabolism of Uric acid can be decreased when combined with Cimetidine. |
| Disulfiram | The serum concentration of Uric acid can be increased when it is combined with Disulfiram. |
| Febuxostat | The serum concentration of the active metabolites of Uric acid can be increased when Uric acid is used in combination with Febuxostat. |
| Fluvoxamine | The metabolism of Uric acid can be decreased when combined with Fluvoxamine. |
| Formoterol | The risk or severity of hypokalemia can be increased when Uric acid is combined with Formoterol. |
| Indacaterol | The risk or severity of adverse effects can be increased when Uric acid is combined with Indacaterol. |
| Isoniazid | The serum concentration of Uric acid can be increased when it is combined with Isoniazid. |
| Lithium citrate | The serum concentration of Lithium citrate can be decreased when it is combined with Uric acid. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be decreased when it is combined with Uric acid. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be decreased when it is combined with Uric acid. |
| Mexiletine | The metabolism of Uric acid can be decreased when combined with Mexiletine. |
| Olodaterol | Uric acid may increase the hyperkalemic activities of Olodaterol. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be decreased when used in combination with Uric acid. |
| Pentoxifylline | The serum concentration of Uric acid can be increased when it is combined with Pentoxifylline. |
| Phenytoin | The serum concentration of Uric acid can be decreased when it is combined with Phenytoin. |
| Fosphenytoin | The serum concentration of Uric acid can be decreased when it is combined with Fosphenytoin. |
| Propafenone | The serum concentration of Uric acid can be increased when it is combined with Propafenone. |
| Quinine | The serum concentration of Uric acid can be increased when it is combined with Quinine. |
| Quinidine | The serum concentration of Uric acid can be increased when it is combined with Quinidine. |
| Riociguat | Uric acid may increase the hypotensive activities of Riociguat. |
| Thiabendazole | The metabolism of Uric acid can be decreased when combined with Thiabendazole. |
| Ticlopidine | The metabolism of Uric acid can be decreased when combined with Ticlopidine. |
| Zafirlukast | The serum concentration of Zafirlukast can be decreased when it is combined with Uric acid. |
| Probenecid | The serum concentration of Uric acid can be increased when it is combined with Probenecid. |
| Isoprenaline | The serum concentration of Uric acid can be decreased when it is combined with Isoprenaline. |
| Amphetamine | The risk or severity of adverse effects can be increased when Amphetamine is combined with Uric acid. |
| Phentermine | The risk or severity of adverse effects can be increased when Phentermine is combined with Uric acid. |
| Midodrine | The risk or severity of adverse effects can be increased when Midodrine is combined with Uric acid. |
| Norepinephrine | The risk or severity of adverse effects can be increased when Norepinephrine is combined with Uric acid. |
| Phenylephrine | The risk or severity of adverse effects can be increased when Phenylephrine is combined with Uric acid. |
| Phenylpropanolamine | The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Uric acid. |
| Labetalol | The risk or severity of adverse effects can be increased when Labetalol is combined with Uric acid. |
| Metaraminol | The risk or severity of adverse effects can be increased when Metaraminol is combined with Uric acid. |
| Epinephrine | The risk or severity of adverse effects can be increased when Epinephrine is combined with Uric acid. |
| Methoxamine | The risk or severity of adverse effects can be increased when Methoxamine is combined with Uric acid. |
| Orciprenaline | The risk or severity of adverse effects can be increased when Orciprenaline is combined with Uric acid. |
| Phenmetrazine | The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Uric acid. |
| Dobutamine | The risk or severity of adverse effects can be increased when Dobutamine is combined with Uric acid. |
| Pseudoephedrine | The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Uric acid. |
| Benzphetamine | The risk or severity of adverse effects can be increased when Benzphetamine is combined with Uric acid. |
| Ritodrine | The risk or severity of adverse effects can be increased when Ritodrine is combined with Uric acid. |
| Terbutaline | The risk or severity of adverse effects can be increased when Terbutaline is combined with Uric acid. |
| Oxymetazoline | The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Uric acid. |
| Diethylpropion | The risk or severity of adverse effects can be increased when Diethylpropion is combined with Uric acid. |
| Dopamine | The risk or severity of adverse effects can be increased when Dopamine is combined with Uric acid. |
| Acebutolol | The risk or severity of adverse effects can be increased when Acebutolol is combined with Uric acid. |
| Lisdexamfetamine | The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Uric acid. |
| Fenoterol | The risk or severity of adverse effects can be increased when Fenoterol is combined with Uric acid. |
| Ephedrine | The risk or severity of adverse effects can be increased when Ephedrine is combined with Uric acid. |
| Mephentermine | The risk or severity of adverse effects can be increased when Mephentermine is combined with Uric acid. |
| Procaterol | The risk or severity of adverse effects can be increased when Procaterol is combined with Uric acid. |
| Clenbuterol | The risk or severity of adverse effects can be increased when Clenbuterol is combined with Uric acid. |
| MMDA | The risk or severity of adverse effects can be increased when MMDA is combined with Uric acid. |
| Midomafetamine | The risk or severity of adverse effects can be increased when Midomafetamine is combined with Uric acid. |
| 2,5-Dimethoxy-4-ethylamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Uric acid. |
| 4-Bromo-2,5-dimethoxyamphetamine | The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Uric acid. |
| Tenamfetamine | The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Uric acid. |
| Chlorphentermine | The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Uric acid. |
| Methylenedioxyethamphetamine | The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Uric acid. |
| Dextroamphetamine | The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Uric acid. |
| Metamfetamine | The risk or severity of adverse effects can be increased when Metamfetamine is combined with Uric acid. |
| Celiprolol | The risk or severity of adverse effects can be increased when Celiprolol is combined with Uric acid. |
| Nylidrin | The risk or severity of adverse effects can be increased when Nylidrin is combined with Uric acid. |
| Tetryzoline | The risk or severity of adverse effects can be increased when Tetryzoline is combined with Uric acid. |
| Tyramine | The risk or severity of adverse effects can be increased when Tyramine is combined with Uric acid. |
| Isoxsuprine | The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Uric acid. |
| Etilefrine | The risk or severity of adverse effects can be increased when Etilefrine is combined with Uric acid. |
| Synephrine | The risk or severity of adverse effects can be increased when Synephrine is combined with Uric acid. |
| Hydroxyamphetamine | The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Uric acid. |
| Iofetamine I-123 | The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Uric acid. |
| Racepinephrine | The risk or severity of adverse effects can be increased when Racepinephrine is combined with Uric acid. |
| Ritobegron | The risk or severity of adverse effects can be increased when Ritobegron is combined with Uric acid. |
| Bucindolol | The risk or severity of adverse effects can be increased when Bucindolol is combined with Uric acid. |
| Tramazoline | The risk or severity of adverse effects can be increased when Tramazoline is combined with Uric acid. |
| Mephedrone | The risk or severity of adverse effects can be increased when Mephedrone is combined with Uric acid. |
| Fenozolone | The risk or severity of adverse effects can be increased when Fenozolone is combined with Uric acid. |
| Methoxyphenamine | The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Uric acid. |
| Tretoquinol | The risk or severity of adverse effects can be increased when Tretoquinol is combined with Uric acid. |
| Gepefrine | The risk or severity of adverse effects can be increased when Gepefrine is combined with Uric acid. |
| Epanolol | The risk or severity of adverse effects can be increased when Epanolol is combined with Uric acid. |
| Prenalterol | The risk or severity of adverse effects can be increased when Prenalterol is combined with Uric acid. |
| Mefenorex | The risk or severity of adverse effects can be increased when Mefenorex is combined with Uric acid. |
| 2,5-Dimethoxy-4-ethylthioamphetamine | The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Uric acid. |
| Esmolol | The risk or severity of adverse effects can be increased when Esmolol is combined with Uric acid. |
| Betaxolol | The risk or severity of adverse effects can be increased when Betaxolol is combined with Uric acid. |
| Metoprolol | The risk or severity of adverse effects can be increased when Metoprolol is combined with Uric acid. |
| Atenolol | The risk or severity of adverse effects can be increased when Atenolol is combined with Uric acid. |
| Timolol | The risk or severity of adverse effects can be increased when Timolol is combined with Uric acid. |
| Sotalol | The risk or severity of adverse effects can be increased when Sotalol is combined with Uric acid. |
| Propranolol | The risk or severity of adverse effects can be increased when Propranolol is combined with Uric acid. |
| Bisoprolol | The risk or severity of adverse effects can be increased when Bisoprolol is combined with Uric acid. |
| Alprenolol | The risk or severity of adverse effects can be increased when Alprenolol is combined with Uric acid. |
| Pindolol | The risk or severity of adverse effects can be increased when Pindolol is combined with Uric acid. |
| Carvedilol | The risk or severity of adverse effects can be increased when Carvedilol is combined with Uric acid. |
| Bevantolol | The risk or severity of adverse effects can be increased when Bevantolol is combined with Uric acid. |